The ITA reports that ju-jitsu athlete Olaf Kepa has accepted a 5-year sanction for his anti-doping rule violation
The International Testing Agency (ITA), on behalf of the Ju-Jitsu International Federation (JJIF), reports that Polish ju-jitsu athlete Olaf Kepa has accepted a 5-year period of ineligibility after testing positive for the prohibited substances metandienone, stenbolone, dehydrochloromethyl-testosterone, drostanolone, anastrozole, octodrine and GW501516.
The ITA, on behalf of JJIF, confirms that the athlete Olaf Kepa has agreed¹ to the consequences for his anti-doping rule violation (ADRV).
The athlete tested positive for metandienone, stenbolone, dehydrochloromethyl-testosterone, drostanolone, anastrozole, octodrine and GW501516 after providing a sample on 4 October 2025 during an in-competition doping control conducted by the ITA at the JJIF European Championship in Beveren, Belgium.
Metandienone, stenbolone, dehydrochloromethyl-testosterone and drostanolone are prohibited under the 2025 and 2026 WADA Prohibited Lists as S1.1 Anabolic Androgenic Steroids (AAS). They are prohibited at all times (in- and out-of-competition) and are classified as non-specified substances. These substances have potent muscle-building and strength-increasing properties.
Anastrozole is prohibited under the 2025 and 2026 WADA Prohibited Lists as S4.1 Hormone and Metabolic Modulators. It is an aromatase inhibitor that reduces estrogen-related side effects of steroid use and helps maintain a higher testosterone-to-estrogen ratio. Anastrozole is a specified substance and is prohibited at all times (in- and out-of-competition).
Octodrine is prohibited under the 2025 and 2026 WADA Prohibited Lists as S6.B Stimulants. It is a central nervous system stimulant that boosts alertness and energy by increasing dopamine and noradrenaline uptake. Octodrine is a specified substance and is prohibited in-competition only.
GW501516 is prohibited under the 2025 and 2026 WADA Prohibited Lists as S4.4 Metabolic Modulators. It is a peroxisome proliferated-activated receptor delta (PPARδ) agonist that activates fat metabolism pathways and improves endurance performance. GW501516 is a non-specified substance and is prohibited at all times (in- and out-of-competition).
When notified of the case, the athlete was provisionally suspended with immediate effect.²
The athlete did not challenge the ADRV and agreed with the consequences for his ADRV under the JJIF Anti-Doping Rules as proposed by the ITA. Accordingly, the case was resolved via an acceptance of consequences.
Due to his early admission of the ADRV, the athlete was entitled to a one-year reduction of the applicable period of ineligibility as set forth in article 10.8.1 of the JJIF anti-doping rules.³
The period of ineligibility, which was increased to five years on the basis of aggravating circumstances,⁴ is from 9 December 2025 until 8 December 2030. Additionally, all the athlete’s individual competitive results at the JJIF European Championship in Beveren, Belgium, and from the date of the sample collection (4 October 2025) until the date of the provisional suspension (9 December 2025) are disqualified.
The decision may be challenged before the appeals division of the Court of Arbitration for Sport (CAS) by the parties with a right of appeal in accordance with Article 13.2.3 of the JJIF anti-doping rules.
The ITA will not comment further on this case.
The original press release can be found here: https://ita.sport/news/the-ita-reports-that-ju-jitsu-athlete-olaf-kepa-has-accepted-a-5-year-sanction-for-his-anti-doping-rule-violation/
